The modern treatment of cardiovascular diseases with b-blockers - focus on the nebivolol.

Abstract

Unlike first-line antihypertensives, nebivolol, a cardioselective b-blocker with vasodilatatory properties caused by its ability to modulate the activity of nitric oxide, positively affects prognosis in patients with arterial hypertension and chronic heart failure and shows metabolic neutrality. The clinical and pathogenetic studies demonstrating the benefits of nebivolol are discussed. Keywords: nebivolol, arterial hypertension, b-blockers.

Keywords

• небиволол
• артериальная гипертензия
• b-блокаторы